Recent Quotes (30 days)

You have no recent quotes
chg | %

Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results forOXB
2.27
-0.03 (-1.52%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 2.19 - 2.35
52 week 1.47 - 3.45
Open 2.30
Vol / Avg. 84,094.00/2,679.00
Mkt cap 32.08M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 1,416.15M
Beta     -
Inst. own     -
*GBP
Aug 23, 2013
Interim 2013 Oxford BioMedica plc Earnings Release Add to calendar
Feb 27, 2013
Preliminary 2012 Oxford BioMedica plc Earnings Conference Call
  

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -113.98% -112.56%
Operating margin -141.80% -135.21%
EBITD margin - 58.01%
Return on average assets -33.04% -34.56%
Return on average equity -46.26% -46.67%
Employees 98 -
Carbon Disclosure Rating - -

Address

Medawar Centre Robert Robinson Avenue The Oxford Science Park
Oxford, ENG OX4 4GA
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

Oxford BioMedica plc is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company�s LentiVector platform products include ProSavin, RetinoStat, StarGen, UshStat, EncorStat, Glaucoma-GT and MoNuDin. Its 5T4 Tumour Antigen produces TroVax and Anti-5T4 antibody. The Prime Boost�s product includes Hi-8 Mel. Its GDEPT platform produces MetXia and Anti Angiogenesis platform produces EndoAngio-GT. The Company is developing four LentiVector platform product candidates for the treatment of ocular diseases: RetinoStat for wet age-related macular degeneration (AMD); StarGen for Stargardt disease; UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. TroVax is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen. On February 25, 2011, the Company purchased a freehold property, United Kingdom comprising a manufacturing facility.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 52
Andrew J. Heath M.D., Ph.D. Deputy Chairman and Senior Independent Director
Age: 64
Tim Watts Chief Financial Officer, Company Secretary, Executive Director
Age: 54
Peter Nolan Senior Vice President - Commercial Development, Executive Director
Age: 59
Stuart Naylor Chief Scientific Officer, Executive Director
Age: 49
Alexander D. Lewis Director - Corporate Activities and Strategy
Age: 47
Nicholas Rodgers Senior Independent Non-Executive Chairman of the Board
Age: 53
Martin Diggle Non-Executive Director
Age: 50
Paul Blake MB, FRCP Non-Executive Independent Director